Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Oculex and Storz sign marketing agreement for ocular product

June 5, 1997

Monarch acquires ocular therapy from Glaxo Wellcome

May 30, 1997

Alphagan introduced in the U.K.

May 29, 1997

Short-acting beta1-adrenoceptor blockers from U. of Melbourne

May 27, 1997

Update on PDT's Purlytin

May 23, 1997

Compounds with dual antiinflammatory/antioxidant activity from Alcon

May 8, 1997

Allergan claims prostaglandin derivatives with vasodilating activity

April 25, 1997

Senju describes new calpain inhibitor

April 10, 1997

IDE sought for new technique for glaucoma surgery

April 2, 1997

Selective CB2 receptor agonists prepared by Merck Frosst

April 2, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...